We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Advair Diskus

News List

Cipla announces completion of phase-3 clinical study for generic version of GSK’s Advair Diskus expresspharma
April 03, 2020
The study, completed in the first attempt, was conducted over a period of 15 months at over 100 sites in the US enrolling 1,400 asthma patients.
Mylan Launches Wixela Inhub americanpharmaceuticalreview
March 11, 2020
Mylan Pharmaceuticals announced the launch of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first available bioequivalent alternative to ADVAIR DISKUS in Canada.
Mylan's generic version of ADVAIR DISKUS for asthma, COPD patients gets FDA approval biospectrumasia
February 02, 2019
The European Medicine Agency has launched a six month consultation on the principles that will form the basis of the electronic product information (ePI)…
FDA approves first generic Advair Diskus worldpharmanews
February 01, 2019
The U.S. Food and Drug Administration approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in...
FDA accepts application for generic version of Advair Diskus europeanpharmaceuticalreview
June 26, 2017
The FDA has accepted Sandoz’s New Drug Application for fluticasone propionate / salmeterol combination product, a generic version of Advair Diskus…